Literature DB >> 8575504

Intravesical application of oxybutynine: mode of action in controlling detrusor hyperreflexia. Preliminary results.

H Madersbacher1, M Knoll.   

Abstract

Topical oxybutynine (Oxy) has been used successfully in neurogenic bladder patients who remained wet on oral anticholinergics or could not tolerate oral medication. However, little is known about the pharmacokinetics of intravesical Oxy. The aim of this study was to evaluate the resorption rate of intravesically given Oxy in the bladder in comparison with oral intake, and to find out which pharmacological properties of the drug are responsible for its effect when given intravesically. Our results indicate that peak plasma levels of intravesical Oxy appear later, are lower and stay longer compared to oral intake. Cystometries before, 20 min and 2 h after intravesical application of Oxy indicate that the main effect of intravesical Oxy on the detrusor is systemic due to its resorption. Our findings confirm the clinical experience that intravesical Oxy is well tolerated, very efficacious and better than oral medication.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8575504     DOI: 10.1159/000475078

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  9 in total

Review 1.  Trospium chloride: a quaternary amine with unique pharmacologic properties.

Authors:  Raymond W Pak; Steven P Petrou; David R Staskin
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 3.092

2.  Renal tract ultrasonography for routine surveillance in spinal cord injury patients.

Authors:  Leonard U Edokpolo; Harris E Foster
Journal:  Top Spinal Cord Inj Rehabil       Date:  2013

Review 3.  Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis.

Authors:  Si-Hong Shen; Xue Jia; Liao Peng; Xiao Zeng; Hong Shen; De-Yi Luo
Journal:  Int Urol Nephrol       Date:  2022-02-28       Impact factor: 2.370

4.  Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder.

Authors:  Mahnoor F Malik; Joseph Hogan Randall; Jack G Campbell; Matthew J McLaughlin; Joel F Koenig
Journal:  Top Spinal Cord Inj Rehabil       Date:  2022-08-17

Review 5.  A benefit-risk assessment of extended-release oxybutynin.

Authors:  Martin C Michel
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  [Overactive bladder--treatment with antimuscarinic agents].

Authors:  K Höfner
Journal:  Urologe A       Date:  2003-05-20       Impact factor: 0.639

Review 7.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Advances in drug delivery: improved bioavailability and drug effect.

Authors:  Roger R Dmochowski; David R Staskin
Journal:  Curr Urol Rep       Date:  2002-12       Impact factor: 2.862

9.  Long-Term Efficacy, Safety, and Tolerability of Modified Intravesical Oxybutynin Chloride for Neurogenic Bladder in Children.

Authors:  Masashi Honda; Yusuke Kimura; Panagiota Tsounapi; Katsuya Hikita; Motoaki Saito; Atsushi Takenaka
Journal:  J Clin Med Res       Date:  2019-03-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.